CINF 20 |
| Although significant advances have been achieved in various toxicological predictions, an attrition rate of drug development up to Phase II appears to be remained at same level over the past 20 years. Sosei's approach to reduce a risk of failure in development by POC study in human is to utilise the compounds that are already know to be tolerable to human. Sosei collect such compounds and incorporate into unique compound library. Sosei, together with technology-based biotechnology companies as an alliance partner, apply various technologies on the library to unlock hidden pharmacology. Development of those once halted compound for new usage enable us to predict lower risk of failure than that of new chemical entities. In addition to this unique strategy, we carry out various reprofiling approaches including conventional medicinal chemistry method and formulation development on existing drugs, in order to leverage the risks in discovery and development, and concurrently maximise business opportunities and revenues. |
|
Drug Reprofiling
2:00 PM-5:40 PM, Sunday, August 19, 2007 BCEC -- 252 A, Oral
Division of Chemical Information |